Merus N.V (MRUS)

Petosemtamab erhielt von der FDA der USA die Breakthrough Therapy Designation

GlobeNewswire Inc.

Merus gibt Finanzergebnisse für das erste Quartal 2024 bekannt und informiert über den aktuellen Geschäftsverlauf

GlobeNewswire Inc.

Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update

GlobeNewswire Inc.

Halozyme Therapeutics (HALO) Q1 Earnings Beat Estimates

Zacks Investment Research

Merus annonce l’acceptation par la FDA américaine et l’examen prioritaire de la demande de licence de produit biologique relative à Zeno dans le traitement du CPNPC et de l’ACP NRG1+

GlobeNewswire Inc.

Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC

GlobeNewswire Inc.

Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?

Zacks Investment Research

Merus (MRUS) Moves 7.1% Higher: Will This Strength Last?

Zacks Investment Research

Will Merus N.V. (MRUS) Report Negative Q1 Earnings? What You Should Know

Zacks Investment Research

Merus annonce les résumés acceptés pour présentation à la réunion annuelle 2024 de l’ASCO

GlobeNewswire Inc.

Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting

GlobeNewswire Inc.

Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024

GlobeNewswire Inc.

Merus participera à une discussion informelle lors de la 23e conférence annuelle Needham Virtual Healthcare

GlobeNewswire Inc.

YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?

Zacks Investment Research

Merus kündigt die Veröffentlichung eines Abstracts für die Präsentation auf der Jahrestagung 2024 der AACR an: Zeno hat sich in Krebsmodellen mit hoher NRG1-Expression als wirksam erwiesen

GlobeNewswire Inc.

Merus annonce ses résultats financiers pour le quatrième trimestre 2023 ainsi que pour l’ensemble de l’exercice 2023 et fait le point sur ses activités

GlobeNewswire Inc.

Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update

GlobeNewswire Inc.

Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks Investment Research

Merus nimmt an bevorstehenden Investorenkonferenzen teil

GlobeNewswire Inc.

Merus to Participate in Upcoming Investor Conferences

GlobeNewswire Inc.

Prothena (PRTA) Surges 12.3%: Is This an Indication of Further Gains?

Zacks Investment Research

Merus N.V. (MRUS) Surges 16.3%: Is This an Indication of Further Gains?

Zacks Investment Research

Wall Street Analysts See a 52.96% Upside in Merus N.V. (MRUS): Can the Stock Really Move This High?

Zacks Investment Research

Biotech stocks set for a rebound in 2024, analysts say

MarketWatch

Biotech stocks set for a rebound in 2024, analysts say

MarketWatch

Wall Street Analysts Think Merus N.V. (MRUS) Could Surge 87.71%: Read This Before Placing a Bet

Zacks Investment Research

Merus N.V. (MRUS) Moves to Buy: Rationale Behind the Upgrade

Zacks Investment Research

Merus präsentiert Zwischenergebnisse zu MCLA-129 auf dem ESMO Asia Congress 2023

GlobeNewswire Inc.

Expert Ratings for Merus

Benzinga

Merus annonce la publication de résumés sur le MCLA-129 à présenter lors de l’édition 2023 du congrès ESMO Asia

GlobeNewswire Inc.

Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023

GlobeNewswire Inc.

Wall Street Analysts See an 85.36% Upside in Merus N.V. (MRUS): Can the Stock Really Move This High?

Zacks Investment Research